4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Financial Results, Press Release
Strengthens Board of Directors with Appointment of Henry Brem, M.D.
Retention Bonuses Approved for CMO Dr. Khurram Jamil and CFO Jack Callicutt
Director Resignation - Marc Rubin Steps Down from Galectin Therapeutics Board
Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit Sufficient to Cover Expected Expenditures Through March 2027
2025 Annual Meeting Results: Directors Elected and Compensation Approved
Announces Exciting Developments Under New Leadership
Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Free Writing Prospectus
Prospectus Filed Pursuant to Rule 424(b)(1)